Skip to main content
. 2017 Sep 21;102(11):1913–1922. doi: 10.3324/haematol.2017.173583

Figure 3.

Figure 3.

Patient satisfaction and preference. (A) Patient satisfaction assessed by (i) RASQ and (ii) CTSQ at cycles 3 and 7, (B) Time taken to receive SC injection/IV infusion (RASQ individual question) at cycle 7, (C) Treatment preferences (RASQ individual question) at cycles 3 and 7. CTSQ: Cancer Therapy Satisfaction Questionnaire; IV: intravenous; RASQ: Rituximab Administration Satisfaction Questionnaire; SC: subcutaneous.